Acta Med. 2016, 59: 22-25

https://doi.org/10.14712/18059694.2016.51

Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still’s Disease

Xavier Vandemergela, Frédéric Vandergheynstb

aDepartment of General Internal Medicine, Centres Hospitaliers Jolimont, Nivelles, Belgium
bCUB Hôpital Erasme, Nivelles, Belgium

Received October 13, 2015
Accepted November 23, 2015

References

1. Stillʼs disease in the adult. Bywaters EG Ann Rheum Dis 1971; 30 (2): 121. <https://doi.org/10.1136/ard.30.2.121> <PubMed>
2. Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine 1991; 70(2): 118. <https://doi.org/10.1097/00005792-199103000-00004>
3. Fitzgerald AA, Leclerq SA, Yan A, Homik JE, Dinarello CA. Rapid Responses to anakinra in patients with refractory adult-onset Still’s disease. Arhtritis Rheum 2005; 52: 1974. <https://doi.org/10.1002/art.21061>
4. de Boysson H, Février J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still’s disease : current clinical evidence. Clin Rheumatol 2013; 32: 141–147. <https://doi.org/10.1007/s10067-012-2105-2>
5. Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: a multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 2014; 66: 1659. <https://doi.org/10.1002/art.38398>
6. Jamilloux Y, Gerfaud-Valentin M, Henry T, Sève P. Treatment of adult-onset Still’s disease: a review. Therapeutics and Clinical Risk Management 2015; 11: 33–43.
7. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use, Arthritis Rheum 2006; 55(3): 420. <https://doi.org/10.1002/art.21984>
8. Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol 1999; 26(2): 373.
9. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum 2010; 62: 2530–2535. <https://doi.org/10.1002/art.27532>
10. Mitamura M, Tada Y, Koarada S, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol 2009; 19: 57–63. <https://doi.org/10.3109/s10165-008-0126-0>
11. Nakamura H, Odani T, Shimizu Y, Takeda T, Kikuchi H. Usefulness of tacrolimus for refractory adult-onset Still’s disease: report of 6 cases. Mod rheumatol 2014; 18: 1–5. <https://doi.org/10.3109/14397595.2014.933997>
12. Bennett AN, Peterson P, Sangle S, et al. Adult onset Still’s disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil. Rheumatology (Oxford) 2004 Jun; 43(6): 795–9. <https://doi.org/10.1093/rheumatology/keh172>
13. Tanaka T, Kishimoto T. Targeting Interleukin-6: All the way to treat autoimmune and inflammatory disease. Int J Biol Sci 2012; 8: 1227–1236. <https://doi.org/10.7150/ijbs.4666> <PubMed>
14. Hoshino T, Ohta A,Yang D, et al. Elevated serum interleukin-6, interferon-gamma and tumor necrosis-alpha levels in patients with adult Still’s disease. J Rheumatol 1998; 25: 396–8.
15. Rueda Gotor J, Blanco Alonso R. Tocilizumab in rheumatoid arthritis. Rheumatol Clin 2011; 6: 29–32.
16. Puéchal X, De Bandt M, Berthelot JM, et al. Tocilizumab in Refractory Adult Still’s Disease. Arthritis Care Research 2011; 1: 155–9. <https://doi.org/10.1002/acr.20319>
17. Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of Adult-onset Still’s disease: Results from a case series. Clin Rheumatol 2014; 33: 49–55. <https://doi.org/10.1007/s10067-013-2381-5>
18. Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: The Israeli Experience. The Journal of Rheumatology 2014; 41: 244–247. <https://doi.org/10.3899/jrheum.130881>
19. Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Still’s disease who was succesfully treated with Tocilizumab over 6 years. Mod Rheumatol 2009; 19: 69–72. <https://doi.org/10.3109/s10165-008-0116-2>
20. Iwamoto M, Nara H, Hirata D, Minota S. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheumat 2002; 46: 3388–9. <https://doi.org/10.1002/art.10620>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive